Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Amylyx Pharmaceuticals, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint asserts that the Individual Defendants made false and misleading statements regarding the Relyvrio commercial launch, claiming significant demand that was not sustainable [2]. - It is alleged that the initial surge in demand for Relyvrio was temporary and had already subsided within months of its launch, undermining growth potential among newly diagnosed ALS patients [2]. - The complaint highlights that there were high, undisclosed discontinuation rates for Relyvrio, which negatively impacted the drug's commercial viability and inflated the perceived potential for acquiring new patients [2]. Legal Representation - Bragar Eagel & Squire, P.C. is representing long-term stockholders of Amylyx and is open to inquiries regarding the claims and rights of investors [3]. Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm specializing in representing individual and institutional investors in various complex litigations across state and federal courts [4].

NEW YORK, May 27, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating The Ensign Group, Inc. (NASDAQ: ENSG) on behalf of the company's shareholders.  The investigation seeks to determine whether The Ensign Group's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of The Ensign Group, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https:/ ...